Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome

ConclusionsUse of a single low-dose regimen of rituximab in the management of frequently relapsing nephrotic syndrome does not affect the probability of relapse at 12 months or time to B cell reconstitution compared to a conventional higher dose.

http://link.springer.com/10.1007/s00467-018-4172-3

Source: Pediatric Nephrology - March 19, 2019 Category: Urology & Nephrology Source Type: research